Ownership Stakes - China Healthwise Holdings Limited holds a 0.62% stake in Huanxi Media Group Limited as of December 31, 2023[1] - The company has a 3.95% ownership in Yuantong Port Development Limited as of December 31, 2023[1] - China Healthwise Holdings Limited owns a 0.19% share in Yunfeng Financial Group Limited as of December 31, 2023[1]

Financial Performance - For the year ended December 31, 2023, the Group's turnover increased by approximately 3% to approximately HK$146 million, compared to approximately HK$142 million for the year ended December 31, 2022[14]. - The gross profit margin for the Reporting Year was approximately 41%, compared to approximately 37% in the Corresponding Year[15]. - The overall loss attributable to owners of the Company was approximately HK$135 million, compared to HK$54 million in the Corresponding Year[15]. - Revenue for the year ended 31 December 2023 was approximately HK$146 million, a 3% increase from approximately HK$142 million in FY22, driven by improved performance in the investment financial instruments and traditional Chinese medicine segments[80]. - The Group recorded a loss attributable to shareholders of approximately HK$135 million in the Reporting Year, compared to approximately HK$54 million in FY22[87][90]. Revenue Segmentation - Revenue from the Chinese health product segment increased from approximately HK$128 million in FY22 to approximately HK$130 million in the Reporting Year[20]. - The Chinese herbal health products segment generated revenue of approximately HK$130 million in the reporting year, an increase from HK$128 million in FY22, with segment profit rising to approximately HK$3 million from HK$2 million in FY22[26]. - Revenue from the money lending segment decreased from approximately HK$15 million in FY22 to approximately HK$11 million in the Reporting Year[20]. - Revenue from the investment in financial instruments improved from a loss of approximately HK$1 million in FY22 to a gain of approximately HK$6 million in FY23[75]. Impairment and Losses - Impairment loss recognized for loan receivables increased from approximately HK$25 million in FY22 to approximately HK$107 million in FY23[21]. - The increase in segment loss was mainly due to an increase of approximately HK$82 million in expected credit loss (ECL) allowance, attributed to loan receivables totaling HK$124 million being reclassified to stage 3 (credit-impaired) during the year[29]. - The total allowance for ECL on loan receivables was approximately HK$294 million, an increase of approximately HK$107 million compared to HK$187 million in FY22[36]. - Impairment loss under the expected credit loss model increased significantly to approximately HK$107 million for the Reporting Year, compared to approximately HK$25 million in FY22, mainly due to the reclassification of 5 loan receivables to stage 3 (credit-impaired)[86][90]. Cash Flow and Assets - As of December 31, 2023, the Group's cash and bank balances were approximately HK$14 million, down from approximately HK$17 million as of December 31, 2022[69]. - Total current assets were approximately HK$140 million, while total current liabilities were approximately HK$143 million, resulting in a current ratio of approximately 0.98[115][116]. - Shareholders' funds decreased significantly from approximately HK$139 million as of December 31, 2022, to approximately HK$4 million as of December 31, 2023, primarily due to operating losses[115][116]. - The value of inventories increased by approximately 2% from approximately HK$55 million as at 31 December 2022 to approximately HK$56 million as at 31 December 2023, with inventory turnover days slightly decreasing to 236 days[100]. Corporate Governance - The Board is committed to high standards of corporate governance, ensuring compliance with all code provisions throughout the year ended December 31, 2023[144]. - The Company has established three committees: Audit, Remuneration, and Nomination, each with defined terms of reference[182]. - The Board comprises six Executive Directors and three Independent Non-executive Directors, with no relationships among members[166]. - All independent non-executive directors have confirmed their independence in accordance with Rule 3.13 of the Listing Rules for the year ended December 31, 2023[187]. Strategic Initiatives - The Group aims to diversify revenue sources through investments and acquisitions of promising businesses or projects[67]. - The Group plans to enhance online sales channels, particularly through platforms like "HKTVmall," which has contributed stable turnover during FY23[55]. - The Group aims to optimize operations using technology and data, including the potential implementation of a Customer Relationship Management System (CRM)[57]. - The Group will participate in shopping promotions and consider live commerce platforms to expand its customer base[57]. Market Outlook - The retail market in Hong Kong is expected to benefit from the full resumption of normal travel between Hong Kong and Mainland China, positively impacting sales[55]. - The demand for health care products, especially Chinese medicine, is expected to grow due to increasing health awareness and an aging population in Hong Kong[54].

Financial Performance - For the fiscal year ending December 31, 2023, China Healthwise Holdings Limited reported total revenue of HKD 146,317,000, an increase of 3% from HKD 142,058,000 in the previous year[2]. - The gross profit for the same period was HKD 60,294,000, representing a growth of 13.5% compared to HKD 53,270,000 in 2022[2]. - The company incurred a net loss of HKD 134,558,000 for the year, which is a significant increase from the net loss of HKD 54,274,000 in the prior year, reflecting a rise of 147%[3]. - The basic and diluted loss per share was HKD 17.46, compared to HKD 7.04 in the previous year, indicating a deterioration in earnings performance[3]. - Total comprehensive loss for the year amounted to HKD 134,251,000, up from HKD 54,415,000 in 2022, marking an increase of 147%[3]. - The company reported a pre-tax loss of HKD 118,243,000, compared to a loss of HKD 45,883,000 in the previous year, indicating a deterioration in financial performance[25]. - The net loss for the fiscal year ending December 31, 2023, was approximately HKD 135.5 million, compared to a loss of HKD 54 million in the previous fiscal year[50]. - The group recorded a loss attributable to shareholders of approximately HKD 135 million, compared to about HKD 54 million in the fiscal year 2022[71]. Assets and Liabilities - The company's total assets decreased to HKD 139,655,000 from HKD 275,017,000 in the previous year, indicating a decline of 49%[5]. - Current liabilities increased to HKD 142,953,000, up from HKD 74,756,000, reflecting an increase of 91%[5]. - The group's total equity as of December 31, 2023, was HKD 4.398 million, a significant decrease from HKD 138.649 million in 2022[10]. - Total liabilities increased to HKD 149,010,000 from HKD 145,272,000, showing a rise in financial obligations[26]. - The total non-current liabilities decreased from HKD 74.254 million in 2022 to HKD 2.319 million in 2023, indicating a significant reduction[10]. - The asset-to-liability ratio was approximately 25.25% as of December 31, 2023, compared to 0.73% as of December 31, 2022[81]. Cash Flow and Financial Condition - Cash and cash equivalents decreased to HKD 14,421,000 from HKD 16,850,000, a decline of 14.4%[5]. - The group plans to actively collect receivables to improve cash flow and financial condition[10]. - The board believes that the cash flow generated from operations will be sufficient to meet the business's funding needs and repay outstanding debts[10]. - The group’s cash and bank balances decreased to approximately HKD 14 million as of December 31, 2023, down from HKD 17 million as of December 31, 2022[81]. Revenue Segments - The revenue from the Chinese medicine health products segment was a significant contributor to the overall income, with no inter-segment sales reported[23]. - The lending business segment generated revenue of HKD 10,656 thousand, down from HKD 14,628 thousand in the previous year, reflecting a decrease[22]. - The investment financial instruments segment reported a revenue of HKD 6,138 thousand, compared to a loss of HKD 945 thousand in the previous year, indicating a recovery[22]. - The Chinese medicine health products segment generated revenue of approximately HKD 130 million, up from about HKD 128 million in the previous fiscal year, contributing a segment profit of approximately HKD 3 million[53]. - The investment financial instruments segment's revenue improved from a loss of approximately HKD 1 million in the fiscal year 2022 to a gain of approximately HKD 6 million in the reporting year[66]. Impairment and Credit Losses - The company reported a significant impairment loss of HKD 107,469,000 related to expected credit losses, compared to HKD 24,784,000 in the previous year[2]. - The expected credit loss provision increased by approximately HKD 82 million due to reclassification of receivables to Stage 3 (credit impaired) during the fiscal year[56]. - The expected credit loss provision for receivables increased to approximately HKD 294 million, up from HKD 187 million in 2022, representing an increase of about HKD 107 million[61]. - The carrying value of receivables from lending operations was HKD 311,313 thousand for the year ended December 31, 2023, down from HKD 320,800 thousand in 2022, with expected credit loss provisions of HKD (186,749) thousand in 2023 compared to HKD (294,218) thousand in 2022[40]. Cost Management - The company is implementing cost-saving measures to control administrative expenses and improve cash flow[10]. - Employee costs, including director remuneration, totaled HKD 42,418,000, indicating a rise in personnel expenses[28]. - The company’s general and administrative expenses were approximately HKD 38 million for the fiscal year ending December 31, 2023, unchanged from the previous fiscal year[70]. - The company incurred interest expenses of HKD 8,993,000, which includes HKD 5,533,000 related to unallocated costs[28]. Governance and Compliance - The company has adhered to all corporate governance guidelines as of December 31, 2023[83]. - The Audit Committee has reviewed the accounting principles and policies adopted by the group for the fiscal year ending December 31, 2023[87]. - There were no purchases, redemptions, or sales of any listed securities by the company or its subsidiaries during the fiscal year ending December 31, 2023[85]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[25]. - The overall financial outlook remains cautious due to the significant losses reported and the need for strategic adjustments moving forward[25]. - The group plans to enhance the promotion of health products, particularly traditional Chinese medicine, due to increasing demand driven by an aging population in Hong Kong[73]. - The online sales channel for traditional Chinese health products is expected to contribute stable revenue through platforms like "HKTVmall" in the fiscal year 2023[74].

Financial Performance - For the fiscal year ending December 31, 2023, the company reported total revenue of HKD 146,317,000, representing an increase of 3.0% from HKD 142,058,000 in the previous year[2]. - The gross profit for the year was HKD 60,294,000, up from HKD 53,270,000, indicating a growth of approximately 13.8%[2]. - The net loss for the year was HKD 134,558,000, compared to a net loss of HKD 54,274,000 in the previous year, reflecting an increase in losses of 147.5%[3]. - The company reported a basic and diluted loss per share of HKD 17.46, compared to HKD 7.04 in the previous year, indicating a significant increase in loss per share[3]. - Total comprehensive loss for the year was HKD 134,251,000, compared to HKD 54,415,000 in the previous year, marking an increase of 147.5%[3]. - The company reported a pre-tax loss of HKD 118,243,000 for the year, compared to a loss of HKD 45,883,000 in the previous year, indicating a significant increase in losses[25]. - The group recorded a loss attributable to shareholders of approximately HKD 135 million, compared to about HKD 54 million in the fiscal year 2022[71]. Assets and Liabilities - The company’s total assets as of December 31, 2023, were HKD 139,655,000, down from HKD 275,017,000 in the previous year, indicating a decrease of 49.3%[5]. - The company’s total liabilities decreased to HKD 142,953,000 from HKD 74,756,000, reflecting an increase of 90.9%[5]. - The total equity as of December 31, 2023, was HKD 4.398 million, a significant decrease from HKD 138.649 million in 2022[10]. - Total assets as of December 31, 2023, amounted to HKD 149,670,000, down from HKD 287,659,000 in the previous year, reflecting a decrease of approximately 48%[26]. - Total liabilities decreased to HKD 145,272,000 from HKD 149,010,000, showing a reduction of about 2%[26]. - The group’s net non-current liabilities decreased from HKD 74.254 million in 2022 to HKD 2.319 million in 2023[10]. Cash Flow and Financial Condition - The company reported a cash and cash equivalents balance of HKD 14,421,000, down from HKD 16,850,000, a decrease of 14.4%[5]. - The group plans to actively collect receivables to improve operating cash flow and financial condition[10]. - The company believes that the cash flow generated from operations will be sufficient to meet business funding needs and repay outstanding debts[10]. - The group is reviewing its investments and considering liquidating certain financial assets to enhance cash flow[10]. - The group’s cash and bank balances were approximately HKD 14 million as of December 31, 2023, down from HKD 17 million as of December 31, 2022[81]. Revenue Segments - The revenue from the Chinese medicine health products segment was a significant contributor to the overall income, with no inter-segment sales reported[23]. - The company has three operating segments: Chinese medicine health products, lending business, and investment financial instruments, each requiring different business strategies[23]. - The lending business segment generated revenue of HKD 10,656 thousand, down from HKD 14,628 thousand in the previous year, reflecting a decrease[22]. - The investment financial instruments segment reported a revenue of HKD 6,138 thousand, compared to a loss of HKD 945 thousand in the previous year, showing improvement[22]. - The Chinese medicine health products segment generated revenue of approximately HKD 130 million, up from about HKD 128 million in the previous fiscal year[53]. Impairment and Credit Losses - The company reported a net impairment loss on receivables of HKD 107,469,000, indicating significant credit risk exposure[28]. - The expected credit loss provision increased to approximately HKD 294 million, up by about HKD 107 million from HKD 187 million in 2022[61]. - The company recognized a significant impairment loss of HKD 107,469 thousand on receivables for the year ended December 31, 2023, compared to HKD 24,784 thousand in 2022[41]. - The expected credit loss model's impairment loss increased to approximately HKD 107 million for the reporting year, compared to about HKD 25 million in the fiscal year 2022[71]. Cost Management - The company’s operating expenses, including selling and administrative expenses, totaled HKD 65,403,000, slightly down from HKD 66,872,000, showing a decrease of 2.2%[2]. - The group has implemented cost-saving measures to control administrative costs and improve cash flow[10]. - Sales and distribution expenses decreased to approximately HKD 28 million, a reduction of about 3% compared to HKD 29 million in the corresponding year[70]. - The cost of goods sold decreased by approximately 3%, amounting to about HKD 86 million in the current fiscal year compared to HKD 89 million in the previous fiscal year[67]. Future Outlook and Strategy - The company plans to focus on expanding its market presence and developing new products in the upcoming fiscal year[25]. - The group plans to enhance online sales channels for traditional Chinese medicine health products, contributing stable revenue through platforms like "HKTVmall" in the fiscal year 2023[74]. - The group aims to attract corporate clients, successfully drawing several charitable organizations to order high-margin health products in the fiscal year 2023[74]. - The group is actively seeking to diversify revenue sources through investments or acquisitions of promising businesses or projects[79]. Governance and Compliance - The company has adhered to all corporate governance rules as of December 31, 2023[83]. - The Audit Committee has reviewed the accounting principles and policies adopted by the group for the fiscal year ending December 31, 2023[87]. - The company has published its performance announcement on the Hong Kong Stock Exchange and its own website[88].

Financial Performance - Revenue for the six months ended 30 June 2023 was HK$80,826,000, representing an increase of 6.7% compared to HK$76,270,000 for the same period in 2022[3]. - Gross profit for the period was HK$33,653,000, up from HK$26,528,000, indicating a gross profit margin improvement[3]. - Loss for the period attributable to owners of the Company was HK$31,862,000, compared to a loss of HK$15,176,000 in the previous year, reflecting a significant increase in losses[4]. - Total comprehensive loss for the period was HK$31,559,000, compared to HK$15,337,000 for the same period in 2022[4]. - The Company reported a basic and diluted loss per share of 1.97 cents, compared to 4.14 cents in the previous year, indicating a reduction in loss per share despite overall losses[4]. - The loss attributable to owners of the Company was approximately HK$32 million, compared to a loss of approximately HK$15 million in the corresponding period[97]. - Loss before income tax for the six months ended June 30, 2023, was HK$31,862,000, compared to a loss of HK$15,176,000 in the same period of 2022, reflecting a significant increase in losses[50]. Cash Flow and Liquidity - Net cash inflow from operating activities was HK$304,000, a recovery from a net outflow of HK$26,204,000 in the prior year[11]. - Cash and cash equivalents at the end of the period decreased to HK$8,843,000 from HK$28,753,000 at the end of the previous period[11]. - Current liabilities decreased to HK$48,715,000 from HK$74,756,000, indicating improved liquidity management[7]. - The current ratio improved to approximately 4.5 as of June 30, 2023, compared to approximately 3.7 as of December 31, 2022[158]. Assets and Liabilities - Total segment assets decreased to HK$233,622,000 as of June 30, 2023, down from HK$287,158,000 at the end of 2022, representing a decline of 18.7%[37]. - Total liabilities decreased to HK$126,851,000 as of June 30, 2023, compared to HK$149,010,000 at the end of 2022, a reduction of 14.8%[37]. - The Company’s equity reserve remained stable at HK$19,835,000 as of June 30, 2023, unchanged from January 1, 2023[13]. - The total accumulated allowance for ECL as of June 30, 2023, was based on a valuation prepared by an independent professional valuer, in accordance with HKFRS 9 Financial Instruments[131]. Revenue Streams - The Company is primarily engaged in the sale of Chinese health products, money lending business, and investment in financial instruments, indicating a diversified revenue stream[26]. - Revenue from contracts with customers for the six months ended June 30, 2023, was HK$80,826,000, a 6.7% increase from HK$76,270,000 in the same period of 2022[27]. - Revenue from trading of Chinese health products increased to HK$70,259,000, up from HK$69,134,000, reflecting a growth of 1.6%[27]. - The Chinese health products business contributed approximately HK$70 million in revenue, representing an increase of approximately 1% from approximately HK$69 million in the corresponding period[99]. Impairment and Credit Losses - Impairment loss on loan receivables under the expected credit loss model was HK$28,334,000, significantly higher than HK$2,547,000 in the previous period[27]. - The allowance for expected credit losses (ECL) rose to HK$215,084,000 as of June 30, 2023, from HK$186,749,000 at December 31, 2022, indicating an increase of 15.2%[55]. - The impairment loss in respect of loan receivables increased from approximately HK$3 million in the corresponding period to approximately HK$28 million in the Period[101]. - The allowance for ECL for loan receivables classified under stage 3 (credit impaired) increased from approximately HK$170 million as of December 31, 2022, to approximately HK$195 million as of June 30, 2023, primarily due to overdue interest and principal on a stage 3 loan for more than three months[118]. Operational Strategies and Future Outlook - The Company has not provided specific guidance for future performance but continues to focus on operational efficiency and cost management strategies[5]. - The Group plans to strengthen the promotion of health care products, including cordyceps sinensis and ginseng, in response to the growing demand for health products in Hong Kong[143]. - Following the resumption of normal travel between Hong Kong and Mainland China, the Group anticipates a positive impact on the retail market and will continue to develop online sales channels for Chinese health products[144]. - The retail industry faces challenges due to inflation and rising costs, but the Group aims to optimize operations using technology and data, including the potential implementation of a Customer Relationship Management System (CRM)[146]. Corporate Governance and Compliance - The Company has complied with all provisions of the Corporate Governance Code throughout the reporting period[193]. - The Audit Committee has reviewed the unaudited condensed interim financial statements for the six months ended June 30, 2023[195]. - The Company has adopted a code of conduct for securities transactions by Directors, confirming compliance throughout the accounting period[194].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：348） 截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 未 經 審 核 中 期 業 績 中國智能健康控股有限公司（「本公司」）董事會（「董事會」或「董事」）欣然公 佈本公司及其附屬公司（統稱「本集團」）截至二零二三年六月三十日止六 個月之未經審核簡明綜合業績，連同截至二零二二年六月三十日止六個 月 同 期 之 比 較 數 字。此 等 中 期 綜 合 財 務 報 表 均 未 經 審 核，惟 已 由 本 公 司 審核委員會審閱。 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 未經審核 截至 截至 二零二三年 二零二二年 六月三十日 六月三十日 止六個月 止六個月 附註 千港元 千港元 ...

Financial Performance - For the year ended December 31, 2022, the Group's turnover decreased by approximately 16% to approximately HK$142 million, compared to approximately HK$170 million for the year ended December 31, 2021[13]. - The gross profit margin for the Reporting Year was approximately 37%, down from approximately 54% in the Corresponding Year[14]. - The overall loss attributable to owners of the Company was approximately HK$54 million, an improvement from HK$103 million in the Corresponding Year[14]. - Revenue from the Chinese health product segment increased from approximately HK$114 million in FY21 to approximately HK$128 million in the Reporting Year[19]. - The money lending segment's revenue decreased from approximately HK$22 million in FY21 to approximately HK$15 million in the Reporting Year[19]. - The Group recorded net realized and unrealized losses on investment in financial instruments of approximately HK$16 million for FY22, compared to gains of approximately HK$18 million for FY21[20]. - Revenue from the investment in financial instruments segment decreased from a gain of approximately HK$34 million in FY21 to a loss of approximately HK$1 million in FY22[73]. - The Group recorded a revenue decrease of approximately 16%, from approximately HK$170 million in FY21 to approximately HK$142 million in FY22[73]. Segment Performance - The increase in revenue from Chinese health products was attributed to the Consumption Vouchers Scheme and the relaxation of social distancing measures by the Hong Kong Government[23]. - As of December 31, 2022, the Chinese health products segment recorded a segment profit of approximately HK$2 million, compared to a loss of HK$9 million in FY21[22]. - The Chinese herbal health products segment generated revenue of approximately HK$128 million in the reporting year, an increase from HK$114 million in FY21, with a segment profit of approximately HK$2 million compared to a loss of HK$9 million in FY21[25]. - The increase in revenue from herbal health products was primarily driven by the Hong Kong government's consumption voucher scheme and the relaxation of certain social distancing measures, which stimulated consumer spending[25]. - The money lending business generated interest income of approximately HK$15 million, down from HK$22 million in FY21, with a segment loss before taxation of approximately HK$30 million, significantly reduced from a loss of HK$98 million in FY21[28]. - The decrease in segment loss in the money lending business was mainly due to a reduction of approximately HK$78 million in the allowance for expected credit loss (ECL) during FY22[28]. Financial Position - As of December 31, 2022, the Group's loan receivables amounted to approximately HK$134 million, a slight decrease from approximately HK$139 million as of December 31, 2021[35]. - The total allowance for ECL on loan receivables was approximately HK$187 million, an increase of approximately HK$25 million compared to FY21[34]. - The Group's total equity at the end of 2022 was HK$57,313,000, a decrease from HK$59,304,000 at the end of 2021, representing a decline of approximately 3.3%[42]. - The Group's cash and bank balances decreased to approximately HK$17 million as of December 31, 2022, from HK$40 million as of December 31, 2021[66]. - Total borrowings increased to approximately HK$31 million as of December 31, 2022, from HK$12 million as of December 31, 2021[66]. - The Group's shareholders' equity decreased from approximately HK$193 million as of December 31, 2021, to approximately HK$139 million as of December 31, 2022, primarily due to operating losses[66]. - The Group's total assets amounted to HK$288 million as of December 31, 2022, financed by shareholders' funds, payables, and borrowings[110][113]. Governance and Risk Management - The Company has complied with all code provisions as set out in the Corporate Governance Code throughout the year ended December 31, 2022[142]. - The Group regularly monitors liquidity and financial position to mitigate liquidity risk[127]. - The Group performs comprehensive due diligence on potential acquisitions to manage strategic risk[126]. - The Company aims to maintain appropriate liquidity to cover financial commitments[127]. - The Group seeks legal advice as appropriate to manage legal and regulatory risks[130]. - The Board has adopted a corporate governance policy to ensure high standards of governance, aligning with the interests of stakeholders[144]. Board Composition and Activities - The Board comprises six Executive Directors and three Independent Non-executive Directors, ensuring a diverse range of skills and expertise[163]. - Fourteen Board meetings were held during the year ended December 31, 2022, ensuring regular oversight and governance[170]. - All Directors are subject to retirement by rotation every three years, ensuring accountability and fresh perspectives[171]. - All independent non-executive directors confirmed their independence in accordance with the Listing Rules for the year ended December 31, 2022[184]. - Continuous professional development activities were participated in by all directors during the reporting year, ensuring their skills remain relevant[193]. - The Board believes that a diversified Board brings constructive challenge and fresh perspectives to discussions[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：348） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 告 業績 中國智能健康控股有限公司（「本公司」）董事會（「董事會」或「董事」）謹此宣 佈本公司及其附屬公司（「本集團」）於截至二零二二年十二月三十一日止 年度之經審核綜合業績連同截至二零二一年十二月三十一日止年度之比 較數字如下： 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 3 142,058 170,079 銷售成本 (88,788) (79,085) ...

Financial Performance - Revenue for the six months ended 30 June 2022 was HK$76,270,000, a decrease of 22% compared to HK$97,897,000 for the same period in 2021[3] - Gross profit for the period was HK$26,528,000, down 52% from HK$55,493,000 in the previous year[3] - Loss for the period attributable to owners of the Company was HK$15,176,000, compared to a profit of HK$36,569,000 in the same period last year[4] - Total comprehensive loss for the period was HK$15,337,000, a significant decline from a comprehensive income of HK$36,361,000 in the prior year[4] - Basic loss per share was (1.97) cents, compared to earnings of 4.75 cents per share in the previous year[4] - For the six months ended June 30, 2022, the company reported a total comprehensive loss of HK$15,337,000, compared to a total comprehensive income of HK$36,361,000 for the same period in 2021[13] - The company recognized a loss of HK$15,176,000 for the period, which is a significant decline compared to a profit of HK$36,569,000 for the same period in the previous year[13] - The gross profit margin for the period was approximately 35%, down from approximately 57% in the corresponding period[98] - The loss attributable to owners of the Company was approximately HK$15 million, compared to a profit of approximately HK$37 million in the corresponding period[98] Cash Flow and Liquidity - Net cash outflow from operating activities was HK$26,204,000, compared to an inflow of HK$13,829,000 in the same period last year[11] - Cash and cash equivalents at the end of the period were HK$28,753,000, a decrease from HK$40,007,000 at the beginning of the period[11] - As of June 30, 2022, the Group's cash and bank balances were approximately HK$29 million, down from approximately HK$40 million as of December 31, 2021[153] - Total borrowings and convertible loan notes increased to approximately HK$103 million as of June 30, 2022, compared to approximately HK$84 million as of December 31, 2021, resulting in a gearing ratio of approximately 58%[153] - The Group's total current assets were approximately HK$222 million, while total current liabilities were approximately HK$127 million, maintaining a current ratio of approximately 1.7[153] Assets and Liabilities - Non-current assets decreased to HK$83,777,000 from HK$112,236,000 as of 31 December 2021[7] - Current liabilities increased to HK$127,231,000 from HK$119,643,000 as of 31 December 2021[8] - Net assets decreased to HK$177,727,000 from HK$193,064,000 as of 31 December 2021[8] - The total liabilities increased to HK$127,898,000 as of June 30, 2022, compared to HK$121,031,000 at the end of 2021, an increase of 5.8%[38] - The Group's shareholders' equity decreased from approximately HK$193 million as of December 31, 2021, to approximately HK$178 million as of June 30, 2022, primarily due to operating losses during the period[153] Revenue Streams - The Group's principal activities include the sale of Chinese health products, money lending, and investment in financial instruments, which are key revenue streams[25] - Revenue from trading Chinese health products increased to HK$69,134,000 for the six months ended June 30, 2022, up from HK$59,873,000 in the same period of 2021, representing a growth of 15.8%[27] - Total revenue from other sources decreased to HK$7,227,000, down from HK$10,988,000, reflecting a decline of 34.5%[27] - The Chinese health products business contributed revenue of approximately HK$69 million during the period, representing an increase of approximately 15% from approximately HK$60 million in the corresponding period[100] - The money lending business generated revenue of approximately HK$7 million during the period, down from approximately HK$11 million in the corresponding period[100] Segment Performance - The segment profit before income tax for Chinese health products was HK$1,865,000, while the money lending business reported a loss of HK$4,720,000, leading to a total reportable segment loss of HK$8,042,000[32] - The Group's money lending business reported a segment loss of approximately HK$5 million, compared to a profit of HK$3 million in the corresponding period[111] - The Group's investment in financial instruments reported a segment loss of approximately HK$5 million for the period, compared to a profit of approximately HK$41 million in 2021, due to stock market deterioration[130] Credit Risk and Impairment - Impairment loss on loan receivables under the expected credit loss model increased to HK$2,547,000 from HK$1,128,000, indicating a rise in credit risk[27] - The accumulated allowance for expected credit losses (ECL) on loan receivables was approximately HK$165 million as of June 30, 2022, an increase of approximately HK$3 million from December 31, 2021[121] - The allowance for ECL for loans classified under stage 3 increased from approximately HK$155 million to approximately HK$157 million, primarily due to prolonged overdue interest and principal payments[119] Operational Developments - The Group plans to continue developing online sales channels for Chinese health products, with financial performance on its online platform and HKTVMall increasing in the first half of 2022[141] - A flagship store was established on Tmall Global in mid-2022 to enhance online presence and sales[141] - The Group aims to broaden its revenue base by targeting youth and middle-class consumers in Hong Kong for its health care products[142] - The Group expects that cost reduction measures, such as renewing rental agreements on more favorable terms, will help maintain a sound financial position[142] Governance and Compliance - The Company has complied with all code provisions of the Corporate Governance Code throughout the six months ended June 30, 2022[193] - The Company has established an Audit Committee to oversee the financial reporting process and risk management systems[200] Miscellaneous - The Group did not recommend the payment of an interim dividend for the six months ended 30 June 2022[97] - The Group did not experience any changes in its capital structure during the period[162] - The Group currently has no foreign currency hedging policy but will monitor foreign exchange risks and consider hedging when necessary[159]

Financial Performance - For the year ended December 31, 2021, the Group's turnover from continuing operations increased by approximately 23% to approximately HK$170 million, compared to approximately HK$138 million for the year ended December 31, 2020[14]. - The gross profit margin from continuing operations for the Reporting Year was approximately 54%, compared to approximately 44% in the Corresponding Year[15]. - The overall loss attributable to owners of the Company was approximately HK$103 million, compared with HK$25 million in the Corresponding Year[15]. - Revenue from the investment in financial instruments segment improved from a loss of HK$4 million in FY20 to a gain of HK$34 million in the Reporting Year[20]. - Revenue from the Chinese health product segment increased slightly from HK$112 million in FY20 to HK$114 million in the Reporting Year[20]. - Revenue from the money lending segment decreased from HK$30 million in FY20 to HK$22 million in the Reporting Year[20]. - The Group recorded a loss attributable to shareholders of approximately HK$103 million in FY21, compared to a loss of approximately HK$25 million in FY20[94]. - The Group recorded a loss of approximately HK$15 million from changes in the fair value of financial assets at fair value through profit or loss in FY21, compared to a loss of HK$5 million in FY20[41]. Investment and Financial Instruments - The net realised and unrealised gains on investment of financial instruments were HK$18 million for FY21, compared to net losses of HK$10 million in FY20[21]. - The investment in financial instruments generated a net gain of approximately HK$34 million in FY21, compared to a net loss of approximately HK$4 million in FY20, resulting in a segment profit of approximately HK$17 million[41]. - The total value of listed equities held by the Group decreased from HK$107.7 million at the beginning of FY21 to HK$59.3 million at the end of FY21, reflecting a loss of HK$48.5 million from disposals[43]. - The Group's significant Hong Kong listed equities include Huanxi Media Group Limited, which had a fair value loss of HK$3.256 million during FY21[46]. Credit Loss and Loan Receivables - The expected credit loss provision on loan receivables increased from HK$49 million in FY20 to HK$103 million in the Reporting Year[21]. - The allowance for expected credit loss (ECL) on loan receivables increased to HK$162 million, a rise of HK$103 million compared to FY20, with HK$155 million recognized for loans classified under stage 3 (credit-impaired)[32]. - The increase in ECL allowance was primarily attributed to the adverse impact of the COVID-19 pandemic on customers' financial conditions and cash flows[36]. - The Group's expected credit loss provisions for receivables have significantly increased due to the adverse financial impact of the COVID-19 pandemic on several clients[39]. - The Group's loan receivables amounted to HK$301 million, an increase from HK$282 million as of December 31, 2020[37]. - The Group granted seven new loans totaling HK$100 million and extended repayment dates for two loans totaling HK$41 million during FY21[29]. - At the end of the Reporting Year, nine loans remained outstanding, with six classified under stage 1 (initial recognition) totaling HK$132 million and three classified under stage 3 (credit-impaired) totaling HK$169 million[34]. Operational Metrics - The Group's online sales channel through "HKTVmall" reported a turnover growth of over 12% during the Reporting Year[55]. - The debtor turnover days improved to 12 days in FY21 from 18 days in FY20[106]. - The Group's total borrowings were approximately HK$12 million as of 31 December 2021, down from HK$20 million as of 31 December 2020[70]. - The current ratio of the Group was approximately 168% as of 31 December 2021, a decrease from 578% as of 31 December 2020[70]. - The Group's shareholders' fund decreased from approximately HK$296 million as of December 31, 2020, to approximately HK$193 million as of December 31, 2021, due to operating losses[70]. Corporate Governance - The Board comprises six Executive Directors and three Independent Non-executive Directors, with no relationships among them[161]. - All Directors confirmed compliance with the Model Code for Securities Transactions during the year ended December 31, 2021[159]. - The Company has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with defined written terms of reference[176]. - The Company has adopted corporate governance policies in line with the Hong Kong Stock Exchange Listing Rules[158]. - The Board is responsible for monitoring management performance and approving financial statements and annual budgets[160]. Future Outlook and Strategy - The Group plans to establish another solely operated "Nam Pei Hong Overseas Flagship Shop" in Tmall Global in 2022 to enhance brand awareness in China[57]. - The Group aims to diversify revenue sources through investments and acquisitions of promising businesses or projects[65]. - The Group's money lending business is expected to face a difficult environment due to the ongoing COVID-19 pandemic[63]. - The Group's operations rely on support from suppliers and financial institutions, with sufficient working capital expected for the next twelve months barring unforeseen circumstances[127].